Description
Clobenzorex Mechanism of Action
Sympathomimetic amine that acts on the ventrolateral nucleus of the hypothalamus, increasing the release of norepinephrine and dopamine in the synaptic spaces and decreasing its reuptake in the presynaptic nerve endings, resulting in an increase in adrenaline and dopamine concentrations. Noradrelin curbs appetite, activating alpha 4 and beta 1 receptors in the hypothalamic nuclei.
Therapeutic indications
Clobenzorex
Tto of patients who are overweight or obese, with any associated pathology and who have not responded to diet and physical activity.
Clobenzorex Dosage
To access the dosage information on Vademecum.es you must connect with your email and password or register.
connectSign up
Clobenzorex contraindications
Hypersensitivity to the components of the formula; elderly or minors of 12-16 years; patients with pulmonary hypertension or severe hypertension; history of cardiovascular or cerebrovascular disease;
psychiatric disorders, including anorexia nervosa and depression; history or predisposition to drug and alcohol use; advanced atherosclerosis; hyperthyroidism; known hypersensitivity or idiosyncrasy to sympathomimetic amines; prostatic hypertrophy or any obstructive condition of the urinary tract; angle-closure glaucoma; agitated states; Do not use concomitantly with other centrally acting anorectics, due to the increased risk of developing life-threatening pulmonary hypertension, nor with antidepressants or MAOIs, should not be administered within 15 days of taking a MAOI due to the risk of presenting hypertensive crisis.
Clobenzorex Warnings and Precautions
Strict medical control; Secondary organic causes of obesity should be excluded before prescribing clobenzorex; include dietary and psychotherapeutic measures; risk of severe pulmonary hypertension, therefore the therapeutic indications and duration of treatment must be respected, a treatment greater than 3 months and a BMI = 30 kg / m2 increases the risk of pulmonary hypertension, the appearance or aggravation of exertional dyspnea suggests the Possibility of pulmonary hypertension, so treatment should be stopped immediately and the patient should go to a specialized center; cardiovascular and cerebrovascular accidents, often after rapid weight loss. In obese patients at risk of enf. Vascular care must be taken to ensure gradual and controlled weight loss; patients with a history of enf. cerebrovascular or cardiovascular; sympathomimetic amines lose anorectic power after several weeks of treatment; Prolonged treatment can cause dependency with withdrawal syndrome when withdrawing treatment. and severe psychotic disorders in predisposed patients; epileptic patients; not interrupt the treatment abruptly, unless it is because of some R. Adv.
Clobenzorex interactions
Adm. 15 days after stopping a treatment with an MAOI, hypertensive crisis could occur; tricyclic antidepressants and serotonin reuptake inhibitors such as venlafaxine and citalopram by increasing the risk of developing serotonin syndrome; Guanetidine or its derivatives by sharing the same place of action and guanetidine and its derivatives could be displaced, reducing its antihypertensive effect; derivatives of phenylethylamine, appetite suppressants such as sibutramine and tricyclic antidepressants, since it can potentiate the effects on blood pressure of the latter; Sympathomimetic agents and anesthetics in general can cause arrhythmias.
Lab: positive reaction in antidoping tests
Reviews
There are no reviews yet.